A Study to Collect Data and Blood Samples from Mayo Patients Who have or are Suspected to have Amyloidosis, or Their Family Members, for Future Research

Overview

About this study

The purpose of this study is to create a data collection and bioregistry of blood samples from Mayo Clinic patients with amyloidosis, suspected amyloidosis, and family members of patients with amyloidosis. This information will be available for future research about this spectrum of diseases.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria

  • Either has or is suspected of having or is the family member of a patient with one of the amyloidoses including, but not limited to
    • Transthyretin
    • Fibrinogen
    • Lysozyme
    • Apolipoprotein-associated
    • Lect-2
    • Serum amyloid A
    • Gelsolin
    • Beta-2 microglobulin
    • Immunoglobulin-associated 
  • Should be able to provide informed consent

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Angela Dispenzieri, M.D.

Open for enrollment

Contact information:

Ann Engebretson L.P.N.

(507)293-1965

Engebretson.Ann@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20168910

Mayo Clinic Footer